IAG Bio-Partnering Team to Attend BIO in Boston, USA

IAG Bio-Partnering Team to Attend BIO in Boston, USA

IAG, CEO, Dr. Olga Kubassova, and lead Bio-Partnering Analyst, Dr. Diana Roettger will be attending BIO 2018 in Boston, USA, from June 1-5. IAG partners with biotechnology and pharmaceutical companies and supports clinical research programs with its scientific, operational and technological expertise. IAG Bio-Partnering division is an independent investment division of IAG that works to build a diversified investment portfolio of innovative life science companies at various stages of clinical development.

The scope of discussions for this conference include:

– Development of clinical stage assets

– IP acquisition from the academic partners and biotech companies

– Investment partnerships

– Strategic collaborations

Given the increasing need for collaboration in therapy development, Dr. Kubassova and Dr. Roettger will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies. To find out more about IAG Bio-Partnering services or to schedule a meeting during BIO 2018 please send an email to contact@ia-grp.com

About BIO 2018

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.  The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries. To find out more information click here.

 

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

News
Events